Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.
Breast Cancer
DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin
Comparison: pCR in nab-paclitaxel/carboplatin vs. nab-paclitaxel/gemcitabine, pCR will be measured after 12 weeks of randomized treatment., After 12 weeks of therapy|Comparison: pCR in responders vs. non-responders, pCR will be measured after 12 weeks of randomized treatment., After 12 weeks of therapy
The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.